This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Ahmed Obeidat, MD, PhD, considers utility of biomarkers in MS diagnosis, but he also noted that diagnosis remains clinical.
Mark Freedman, MD, MSc, engages Ahmed Obeidat, MD, PhD, in discussing the role of biomarkers, specifically neurofilament light, in diagnosing multiple sclerosis (MS). Ahmed Obeidat, MD, PhD, emphasizes that MS remains a clinical diagnosis, relying on patient narratives, clinical examinations, and traditional biomarkers like MRI.
He acknowledges the interest in neurofilament light due to studies suggesting its elevation before an MS diagnosis, such as in cases with Epstein-Barr virus infection. Ahmed Obeidat, MD, PhD, highlights potential advantages in early MS detection, noting instances where neurofilament light elevation preceded clinical symptoms.
Mark Freedman, MD, MSc, probes the temporal relationship between MRI lesions and neurofilament elevation. Ahmed Obeidat, MD, PhD, acknowledges conflicting literature, suggesting neurofilament light might lag behind MRI findings in certain treatments. He expresses appreciation for biomarkers, considering them as part of the diagnostic puzzle but not standalone.
The discussion touches on the possibility of diagnosing MS without clinical attacks. Ahmed Obeidat, MD, PhD, agrees with the notion, referencing cases like radiologically isolated syndrome. He emphasizes the importance of considering abnormal cognitive assessments and elevated neurofilament light in such scenarios, indicating a willingness to intervene early.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.